Vertex Pharmaceuticals encountered a challenging first quarter in 2025, as both revenue and non-GAAP profit fell short of Wall Street expectations, leading to a significant negative market reaction. Management attributed the subdued performance to factors including slower-than-anticipated uptake for newly launched products and specific regional pressures, such as a decline in ex-U.S. cystic fibrosis (CF) revenues due to market dynamics in Russia. CEO Reshma Kewalramani acknowledged, “Russia revenue was negatively impacted by the availability of an illegal copy product,” resulting in a notable headwind for the quarter. Increased research, development, and commercial spending—particularly for pain and kidney disease programs—also weighed on operating margins.
Is now the time to buy VRTX? Find out in our full research report (it’s free).
Vertex Pharmaceuticals (VRTX) Q1 CY2025 Highlights:
- Revenue: $2.77 billion vs analyst estimates of $2.83 billion (3% year-on-year growth, 2.3% miss)
- Adjusted EPS: $4.06 vs analyst expectations of $4.29 (5.4% miss)
- Adjusted EBITDA: $1.23 billion vs analyst estimates of $1.31 billion (44.5% margin, 6.2% miss)
- The company reconfirmed its revenue guidance for the full year of $11.88 billion at the midpoint
- Operating Margin: 22.7%, down from 42.4% in the same quarter last year
- Market Capitalization: $114.5 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions Vertex Pharmaceuticals’s Q1 Earnings Call
-
Geoffrey Meacham (Citibank) asked if the ALYFTREK launch was driven more by dosing convenience or clinical biomarkers. Chief Commercial Officer Stuart Arbuckle replied that uptake is due to a combination of noninferiority to existing therapies, improved CFTR function, expanded mutation coverage, and once-daily dosing.
-
Jessica Fye (JPMorgan) questioned exposure to tariffs and the impact of the Russia market. CFO Charles Wagner clarified that Vertex’s supply chain has minimal exposure to China, with most CF drug manufacturing and intellectual property based in the U.S. and U.K., and that the Russian revenue impact is isolated and already included in guidance.
-
Salveen Richter (Goldman Sachs) probed early patient segments for ALYFTREK and payer coverage for JOURNAVX. Arbuckle confirmed fastest uptake among newly eligible patients, while McKechnie emphasized ongoing efforts to secure broad, low-restriction coverage and optimize long-term value for the company.
-
Tazeen Ahmad (BofA Merrill Lynch) inquired about the settings and patient profiles for JOURNAVX prescriptions. Duncan McKechnie explained that the medication is being adopted for both surgical and non-surgical acute pain across various specialties, with early use concentrated in discharge settings, and noted that initial volumes will precede significant revenue as payer coverage ramps.
-
Evan Seigerman (BMO Capital Markets) asked about hurdles to CASGEVY adoption. Arbuckle identified the need for more authorized treatment centers, payer coverage, and increased familiarity among treatment centers with the complex therapy process as key factors influencing uptake.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) the pace of patient transitions to ALYFTREK, especially as regulatory approvals expand globally, (2) the ramp-up in JOURNAVX revenue as payer coverage and hospital formulary access broaden, and (3) progress on pivotal clinical trials in pain, diabetes, and kidney disease. Execution on these fronts, as well as the ability to control operating expenses, will be important indicators of Vertex’s ability to deliver on its growth strategy.
Vertex Pharmaceuticals currently trades at $443.40, down from $499.76 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
Donald Trump’s victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
